Cost-effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
暂无分享,去创建一个
H. Black | D. Weir | W. Elliott | H R Black | W J Elliott | D R Weir | D. R. Weir
[1] M. Johannesson,et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. , 1997, The New England journal of medicine.
[2] T. Olsen,et al. Acute stroke: Prognosis and a prediction of the effect of medical treatment on outcome and health care utilization , 1997, Neurology.
[3] J. Miller,et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. , 1995, Hypertension.
[4] J. Manson,et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. , 1991, Archives of internal medicine.
[5] Erry,et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. , 1995, The New England journal of medicine.
[6] R. Rodby,et al. An Economic Analysis of Captopril in the Treatment of Diabetic Nephropathy , 1996, Diabetes Care.
[7] A J Belanger,et al. Epidemiology of heart failure. , 1991, American heart journal.
[8] P. Wolf,et al. Black-white differences in stroke incidence in a national sample. The contribution of hypertension and diabetes mellitus. , 1990, JAMA.
[9] C. Mulrow,et al. The J-curve phenomenon and the treatment of hypertension. Is there a point beyond which pressure reduction is dangerous? , 1991, JAMA.
[10] V. Hasselblad,et al. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. , 1997 .
[11] V. Hasselblad,et al. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. , 1997, JAMA.
[12] I. Stewart. RELATION OF REDUCTION IN PRESSURE TO FIRST MYOCARDIAL INFARCTION IN PATIENTS RECEIVING TREATMENT FOR SEVERE HYPERTENSION , 1979, The Lancet.
[13] G A Colditz,et al. The economic costs of non-insulin-dependent diabetes mellitus. , 1989, JAMA.
[14] L. Goldman,et al. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. , 1990, JAMA.
[15] J. Neaton,et al. Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial , 1993, Diabetes Care.
[16] R. Collins,et al. Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.
[17] P. Sandercock,et al. Long‐term Survival After First‐Ever Stroke: The Oxfordshire Community Stroke Project , 1993, Stroke.
[18] Detection. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .
[19] A. Levey,et al. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. , 1997, Annals of internal medicine.
[20] M. Weinstein,et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.
[21] S. Glantz,et al. Short-term economic and health benefits of smoking cessation: myocardial infarction and stroke. , 1997, Circulation.
[22] J F Fries,et al. Aging, health risks, and cumulative disability. , 1998, The New England journal of medicine.
[23] H. Jacobson,et al. Report on a workshop to develop management recommendations for the prevention of progression in chronic renal disease. , 1995, Nihon Jinzo Gakkai shi.
[24] J. Cruickshank,et al. BENEFITS AND POTENTIAL HARM OF LOWERING HIGH BLOOD PRESSURE , 1987, The Lancet.
[25] E. Ford,et al. Risk factors for mortality from all causes and from coronary heart disease among persons with diabetes. Findings from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. , 1991, American journal of epidemiology.
[26] B. Psaty,et al. Cost-minimization and the number needed to treat in uncomplicated hypertension. , 1998, American journal of hypertension.
[27] R. Vasan,et al. The progression from hypertension to congestive heart failure. , 1996, JAMA.
[28] R. Bain,et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.
[29] J. Madans,et al. Mortality among diabetics in a national sample. , 1988, American journal of epidemiology.
[30] Philip D. Harvey,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.
[31] Joël Ménard,et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.
[32] R. Holman,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .
[33] D K Owens,et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. , 1995, JAMA.
[34] Philip D. Harvey,et al. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 , 1998, BMJ.
[35] S. Mohiuddin,et al. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension. , 1994, Clinical therapeutics.
[36] K. Anderson,et al. Cardiovascular disease risk profiles. , 1991, American heart journal.
[37] M. Moser,et al. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. , 1996, Journal of the American College of Cardiology.
[38] Lippincott Williams Wilkins,et al. National High Blood Pressure Education Program Working Group Report on Hypertension in Diabetes , 1994, Hypertension.
[39] R B D'Agostino,et al. Probability of stroke: a risk profile from the Framingham Study. , 1991, Stroke.
[40] J. Holmes,et al. Lifetime cost of stroke in the United States. , 1996, Stroke.
[41] W. O'Fallon,et al. Chronic renal failure in non-insulin-dependent diabetes mellitus. A population-based study in Rochester, Minnesota. , 1989, Annals of internal medicine.
[42] B. Davis,et al. Prevention of Heart Failure by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension , 1997 .
[43] A. Folsom,et al. Trends in Survival of Hospitalized Myocardial Infarction Patients Between 1970 and 1985: The Minnesota Heart Survey , 1992, Circulation.
[44] S. Perreault,et al. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective? , 1998, Archives of internal medicine.